Shares of the biotech Can-Fite Biopharma Ltd CANF were skyrocketing Monday after an abstract describing data from the company's liver cancer study of the drug namodenoson was selected by the International Liver Cancer Association conference.
Can-Fite shares were rallying by 64.47 percent at $8.47 at the time of publication Monday.
A Phase 3 trial for namodenoson in advanced liver cancer is now under preparation, the company said.
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor.
"This is a very prestigious conference that brings together the leading thought leaders, researchers, and physicians in the treatment of liver cancer. Governing members of the ILCA thoroughly research each abstract submission and select those that are most relevant to the advancement of treating liver cancer," CEO Pnina Fishman said in a statement.&
Update: On Monday afternoon, Can-Fite reported a $6 million registered direct offering.
Related Links:
Mid-Morning Market Update: Markets Open Lower; International Game Technology Earnings Miss Views
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
